
ACADIA Pharmaceuticals Inc.: updates and filings
Price
$17.52
November 19, 2026Market cap $3.0B
What Ploutos Investor adds for ACADIA Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- Most of the reported profit is a tax credit, not money earned from customers. We leave out the P/E and the earnings growth, which would not compare with a company that paid tax.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 4, 2026next Feb 4, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
October 2026
September 2026
August 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 10, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 5, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 4, 2026Results of operationsForm8-K
- Oct 23, 2026Officer or director changeForm8-K
- Sep 24, 2026Regulation FD disclosure, other material eventsForm8-K
- Sep 11, 2026Other material eventsForm8-K
- Aug 7, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 5, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 4, 2026Results of operationsForm8-K
- Jun 10, 2026Shares registered for employeesFormS-8
- May 29, 2026Officer or director change, shareholder voteForm8-K
- May 7, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 6, 2026Results of operationsForm8-K
- May 1, 2026Officer or director change, Regulation FD disclosureForm8-K
- Apr 28, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 24, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 24, 2026Annual meeting proxy statementFormDEF 14A
- Mar 26, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 5, 2026Officer or director changeForm8-K
- Feb 26, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Feb 26, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 25, 2026Results of operationsForm8-K
- Jan 13, 2026Results of operations, Regulation FD disclosureForm8-K
- Nov 14, 2025Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 6, 2025Quarterly reportfor the period to Sep 30, 2025Form10-Q
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 10, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 5, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 4, 2026 | 8-K | Results of operations | Document |
| Oct 23, 2026 | 8-K | Officer or director change | Document |
| Sep 24, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Sep 11, 2026 | 8-K | Other material events | Document |
| Aug 7, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 5, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 4, 2026 | 8-K | Results of operations | Document |
| Jun 10, 2026 | S-8 | Shares registered for employees | Document |
| May 29, 2026 | 8-K | Officer or director change, shareholder vote | Document |
| May 7, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 6, 2026 | 8-K | Results of operations | Document |
| May 1, 2026 | 8-K | Officer or director change, Regulation FD disclosure | Document |
| Apr 28, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 24, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 24, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 26, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 5, 2026 | 8-K | Officer or director change | Document |
| Feb 26, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Feb 26, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 25, 2026 | 8-K | Results of operations | Document |
| Jan 13, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Nov 14, 2025 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 6, 2025 | 10-Q | Quarterly reportfor the period to Sep 30, 2025 | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Dec 21, 2000.
The full analysis
What do ACADIA Pharmaceuticals's filings show?
The filings are where every one of ACADIA Pharmaceuticals's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.